In a bid to expand its pipeline of Personalized Healthcare assays, Qiagen NV (QGEN – Snapshot Report) acquired an exclusive worldwide license for the calreticulin (CALR) biomarker from CeMM Vienna, the Research Center for Molecular Medicine of the Austrian Academy of Sciences.
Qiagen retains a strong pipeline of promising biomarkers under development for Personalized Healthcare tests pertaining to rheumatoid arthritis, lung cancer, colorectal cancer, glioblastoma, lymphoma and other cancers. Post acquisition of the license, Qiagen will develop a molecular diagnostic test for CALR mutations that will help healthcare providers to make more informed therapeutic decisions.
{iframe}http://www.zacks.com/stock/news/129637/qiagen-expands-personalized-healthcare-pipeline{/iframe}